MiR-451 as a new tumor marker for gastric cancer

Yong Shen; Jiao-Mei Gong; Li-Li Zhou; Jia-He Sheng

doi:10.18632/oncotarget.17239

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2019; 10:6396-6396.

MiR-451 as a new tumor marker for gastric cancer

Yong Shen _, Jiao-Mei Gong, Li-Li Zhou and Jia-He Sheng

PDF | HTML | How to cite

Oncotarget. 2017; 8:56542-56545. https://doi.org/10.18632/oncotarget.17239

Metrics: PDF 2191 views | HTML 2406 views | ?

Abstract

Yong Shen1,2, Jiao-Mei Gong3, Li-Li Zhou4 and Jia-He Sheng1

1Department of Clinical Laboratory, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China

2Department of Pathology and Pathophysiology, Medical School of Southeast University, Nanjing, Jiangsu, China

3Department of Clinical Laboratory, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

4Department of Hepatobiliary Surgery, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China

Correspondence to:

Yong Shen, email: [email protected]

Keywords: MiR-451, gastric cancer, diagnoses, pathology

Received: March 03, 2017 Accepted: March 23, 2017 Published: April 19, 2017

ABSTRACT

Gastric cancer is the second most common malignancy in China. However, the prognosis for gastric cancer patients remains poor. The purpose of this study was to investigate whether miR-451 was a potential prognostic biomarker for gastric cancer. Fresh tissues were immediately frozen in liquid nitrogen until use. The plasma was extracted and quantitative real-time polymerase chain reaction was performed to detect miR-451 expression. The Student’s t test analysis and multivariate Cox regression analysis were performed to analyze expression of miR-451. The analysis results showed that the expression level of miR-451 was decreased expression in gastric cancer tissue. The down-regulation of miR-451 tended to be positively correlated with tumor stage, lymphatic metastasis and shorter overall survival of patients. MiR-451 may be a potential biomarker and a potential therapeutic target for the diagnoses and prognosis of gastric cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17239

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

MiR-451 as a new tumor marker for gastric cancer

Abstract